We thank Joshua McMichael for assistance with figure design and Nicole Maher for critical review of the manuscript.
Genomic tools in acute myeloid leukemia: From the bench to the bedside
Article first published online: 28 JAN 2014
© 2013 American Cancer Society
Volume 120, Issue 8, pages 1134–1144, 15 April 2014
How to Cite
White, B. S. and DiPersio, J. F. (2014), Genomic tools in acute myeloid leukemia: From the bench to the bedside. Cancer, 120: 1134–1144. doi: 10.1002/cncr.28552
- Issue published online: 8 APR 2014
- Article first published online: 28 JAN 2014
- Manuscript Accepted: 14 NOV 2013
- Manuscript Received: 25 SEP 2013
- acute myeloid leukemia;
- high-throughput nucleotide sequencing;
- gene expression profiling
Since its use in the initial characterization of an acute myeloid leukemia (AML) genome, next-generation sequencing (NGS) has continued to molecularly refine the disease. Here, the authors review the spectrum of NGS applications that have subsequently delineated the prognostic significance and biologic consequences of these mutations. Furthermore, the role of this technology in providing a high-resolution glimpse of AML clonal heterogeneity, which may inform future choice of targeted therapy, is discussed. Although obstacles remain in applying these techniques clinically, they have already had an impact on patient care. Cancer 2014;120:1134–1144. © 2014 American Cancer Society.